Go Pro
NASDAQ:GLSI

Greenwich LifeSciences Q2 2026 Earnings Report

Greenwich LifeSciences logo
$14.62 +0.55 (+3.94%)
Closing price 03:59 PM Eastern
Extended Trading
$14.49 -0.13 (-0.92%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Greenwich LifeSciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.34
Beat/Miss
N/A
One Year Ago EPS
N/A

Greenwich LifeSciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Greenwich LifeSciences Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Greenwich LifeSciences Earnings Headlines

Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
Greenwich LifeSciences The Overlooked Need
See More Greenwich LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Greenwich LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Greenwich LifeSciences and other key companies, straight to your email.

About Greenwich LifeSciences

Greenwich LifeSciences (NASDAQ:GLSI) (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States. The company leverages proprietary technologies to identify immune-modulating compounds and works with contract research organizations to support its preclinical and clinical programs.

Greenwich LifeSciences pursues strategic collaborations and licensing arrangements to expand its scientific expertise and accelerate the progress of its therapeutic candidates. With a focus on unmet medical needs in oncology and inflammatory disorders, the company aims to bring first-in-class or best-in-class treatments to patients through disciplined clinical development and regulatory strategies.

View Greenwich LifeSciences Profile